PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
91.74%
Net income growth above 1.5x AVXL's 33.05%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-100.00%
Negative yoy D&A while AVXL is 0.22%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
100.00%
Deferred tax of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-95.76%
Negative yoy SBC while AVXL is 100.00%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-167.13%
Both reduce yoy usage, with AVXL at -24.34%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-230.77%
Both negative yoy AP, with AVXL at -85.96%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-79.38%
Negative yoy usage while AVXL is 100.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-151.83%
Both negative yoy, with AVXL at -28.06%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
55.51%
Operating cash flow growth 1.25-1.5x AVXL's 47.77%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
52.86%
CapEx growth of 52.86% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.86%
We expand invests by 52.86% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.